Search details
1.
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med
; 389(21): 1961-1971, 2023 Nov 23.
Article
in English
| MEDLINE | ID: mdl-37870920
2.
Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience.
J Urol
; 211(2): 241-255, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37922370
3.
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.
J Natl Compr Canc Netw
; 22(4): 216-225, 2024 05.
Article
in English
| MEDLINE | ID: mdl-38754471
4.
Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.
Future Oncol
; 20(5): 231-243, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37916514
5.
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Lancet Oncol
; 23(2): 248-258, 2022 02.
Article
in English
| MEDLINE | ID: mdl-35030333
6.
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med
; 381(4): 338-348, 2019 07 25.
Article
in English
| MEDLINE | ID: mdl-31340094
7.
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
J Natl Compr Canc Netw
; 20(8): 866-878, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35948037
8.
Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now.
Curr Treat Options Oncol
; 23(9): 1269-1287, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35962938
9.
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.
Cancer
; 127(6): 840-849, 2021 03 15.
Article
in English
| MEDLINE | ID: mdl-33216356
10.
Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
J Urol
; 206(5): 1258-1267, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34184926
11.
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.
Future Oncol
; 17(24): 3137-3150, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-34008425
12.
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
Future Oncol
; 17(2): 137-149, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-32938232
13.
Emerging treatments in advanced urothelial cancer.
Curr Opin Oncol
; 32(3): 232-239, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32209822
14.
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(3): 329-354, 2020 03.
Article
in English
| MEDLINE | ID: mdl-32135513
15.
Evolution of front-line immunotherapy for metastatic urothelial cancer.
Lancet Oncol
; 25(1): 2-3, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38101432
16.
Targeting advanced urothelial carcinoma-developing strategies.
Curr Opin Oncol
; 31(3): 207-215, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30844889
17.
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
World J Urol
; 37(1): 95-105, 2019 Jan.
Article
in English
| MEDLINE | ID: mdl-30238401
18.
Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses.
Int J Clin Oncol
; 24(9): 1089-1098, 2019 Sep.
Article
in English
| MEDLINE | ID: mdl-31218529
19.
Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.
J Urol
; 199(5): 1129-1142, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29113841
20.
Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy.
BJU Int
; 122(1): 89-98, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29569824